Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT00908999 | Completed

• 1 other identifier: HSC-2008-0090
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is a three year fMRI study conducted at the University of Wisconsin (UW) Hospital and the William. S. Middleton VA Hospital. This study is guided by the hypothesis that reduced fMRI activity and connectivity cortical midline structures (i.e., medial frontal and ventral posterior cingulate cortex) are physiologic abnormalities that relate strongly to the compromised insight into cognitive deficits, or anosognosia, shown by a subset of individuals with amnestic MCI (aMCI) and AD. Further, the investigators hypothesize that these regional changes in fMRI activity are predictive of faster progression from aMCI to AD.

Conditions

Anosognosia; Alzheimer's Disease; Mild Cognitive Impairment

Keywords

anosognosia fMRI amnestic MCI Alzheimer; anosognosia in AD and MCI

Study Arms (3)

Controls

The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.

amnestic Mild Cognitive Impairment

Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.

Alzheimer's disease

Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.

Eligibility Criteria

• Age: 60 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

MCI and AD patients are referred from memory clinics at the UW hospital, William S. Middleton Memorial Veterans Hospital (Madison, WI) and the statewide clinics offered through the Wisconsin Alzheimer's Institute (WAI).

You may qualify if:

• Amnestic MCI:
• Observation of memory decline by informant.
• Mini Mental Status Exam (MMSE) score between 24 and 30.
• Objective memory impairment on neuropsychological tests.
• Intact functional abilities, and 4) no diagnosis of dementia.
• AD:
• A diagnosis of probable AD according with the NINDS-ADRDA and DSM-IV diagnostic criteria.
• MMSE score between 16 and 27. All AD patients will have capacity to provide informed consent as judged by the referring physician.

You may not qualify if:

• MRI incompatibility; history of neurologic disease (including prior loss of consciousness of more than 10 minutes); prior neurosurgery; or chronic medical diseases (such as poorly controlled diabetes, renal disease, or poorly controlled hypertension).
• Excluded medications include neuroleptics, short or long acting nitrates, and Warfarin.

Sponsors & Collaborators

• University of Wisconsin, Madison: lead

Study Sites (1)

William S Middleton VA Hospital GRECC

Madison, Wisconsin, 53705, United States

Location

MeSH Terms

Conditions

Agnosia; Alzheimer Disease; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Dementia; Brain Diseases; Central Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2009
• First Posted: May 27, 2009
• Study Start: April 1, 2008
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: September 29, 2011

Record last verified: 2011-09

Locations

US (1)